# Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease

> **NCT04109300** · NA · UNKNOWN · sponsor: **Western University, Canada** · enrollment: 162 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases
- Ulcerative Colitis
- Crohn Disease

## Interventions

- **GENETIC:** HLADQA1*05A>G screening
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04109300
- **Lead sponsor:** Western University, Canada
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04109300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04109300, "Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT04109300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*